Search

Krystal Biotech Inc

Закрыт

СекторЗдравоохранение

344.47 0.84

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

336.21

Макс.

351.1

Ключевые показатели

By Trading Economics

Доход

-1.2M

55M

Продажи

2.9M

119M

P/E

Средняя по отрасли

41.888

55.725

Прибыль на акцию

1.79

Рентабельность продаж

45.938

Сотрудники

295

EBITDA

2.9M

66M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+15.14% upside

Дивиденды

By Acuity

Следующий отчет о доходах

2 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-490M

9.9B

Предыдущая цена открытия

343.63

Предыдущая цена закрытия

344.47

Новостные настроения

By Acuity

29%

71%

54 / 339 Рейтинг в Healthcare

Krystal Biotech Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 сент. 2026 г., 20:02 UTC

Krystal Biotech Inc shares fell sharply, remaining below the 20-day moving average and near the lower end of their one-month range.

22 сент. 2026 г., 23:31 UTC

Krystal Biotech Inc is advancing in after-market trading, gaining notably since Tuesday's close and trading well above its 20-day moving average.

21 сент. 2026 г., 19:35 UTC

Krystal Biotech Inc shares fell, trading below Friday's close and under its 20-day moving average after pulling back from an earlier session high.

18 сент. 2026 г., 20:13 UTC

Krystal Biotech Inc is trading modestly higher in after-market hours, reflecting broader market gains amid rising Treasury yields and mixed economic signals.

15 сент. 2026 г., 19:36 UTC

Krystal Biotech Inc shares are lower today, continuing a decline since Monday amid rising treasury yields that are pressuring broader market sentiment.

10 сент. 2026 г., 20:07 UTC

Krystal Biotech Inc shares are lower amid a broader market downturn influenced by rising Treasury yields and heightened inflation concerns. No specific company news was identified.

9 сент. 2026 г., 20:07 UTC

Krystal Biotech Inc shares are declining, continuing a three-day downward trend amid rising crude oil prices and no specific company news identified.

8 сент. 2026 г., 20:07 UTC

News

Krystal Biotech shares are lower as the market declines amid volatility. Odyssean LLC increased its stake by 94%, now holding shares valued at $3.48 million.

4 сент. 2026 г., 20:01 UTC

Krystal Biotech Inc shares are lower amid broader market pressures and rising Treasury yields. No specific company news was identified for the decline.

2 сент. 2026 г., 19:36 UTC

Krystal Biotech Inc shares are higher today, reaching a session peak before retracing some gains. The stock remains above its 20-day moving average.

1 сент. 2026 г., 23:41 UTC

Krystal Biotech Inc shares are lower in after-market hours, declining from earlier highs despite being above the 20-day moving average. No specific news was identified.

31 авг. 2026 г., 20:02 UTC

Krystal Biotech Inc's shares are higher today, showing notable intraday volatility and remaining above their 20-day moving average. No specific news was identified.

25 авг. 2026 г., 20:07 UTC

Krystal Biotech Inc shares are higher today, benefiting from easing Treasury yields and strong momentum, despite no specific company news driving the move.

24 авг. 2026 г., 19:16 UTC

Krystal Biotech Inc's shares are lower today, continuing a decline since Friday. Market focus remains on upcoming economic events amid inflation concerns.

21 авг. 2026 г., 21:01 UTC

Krystal Biotech shares are lower in after-market trading, reflecting a modest decline since Friday's close amid limited price fluctuations.

20 авг. 2026 г., 21:01 UTC

Krystal Biotech Inc shares are higher in after-market trading, maintaining a position above their 20-day moving average without any specific news to explain the rise.

19 авг. 2026 г., 20:02 UTC

Correlated Moves

Shares rise amid positive momentum in biotechnology sector.

14 авг. 2026 г., 19:46 UTC

News

RBC Capital initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, boosting shares higher since Thursday's close.

13 авг. 2026 г., 19:46 UTC

Correlated Moves

Krystal Biotech Inc shares are lower, reflecting a broader decline in the biotechnology sector and trading below their 20-day moving average.

12 авг. 2026 г., 20:52 UTC

Krystal Biotech Inc shares declined during after-market hours, trading near the lower end of its one-month range and below its 20-day moving average.

11 авг. 2026 г., 21:01 UTC

Krystal Biotech Inc. shares rose in after-market trading, reaching a high of 1.23% above Tuesday's close, despite remaining below its 20-day moving average.

7 авг. 2026 г., 19:26 UTC

Krystal Biotech Inc shares are higher during Friday's session, reflecting a gain since Thursday's close. No specific news was identified to explain the movement.

6 авг. 2026 г., 19:26 UTC

Shares of Krystal Biotech Inc. are lower today, trading near the lower end of their one-month range and below the 20-day moving average.

5 авг. 2026 г., 19:52 UTC

Krystal Biotech Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is cautious following ADP's weak employment report.

4 авг. 2026 г., 20:04 UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

3 авг. 2026 г., 23:06 UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

31 июл. 2026 г., 23:06 UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

30 июл. 2026 г., 19:39 UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

29 июл. 2026 г., 20:04 UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

28 июл. 2026 г., 20:03 UTC

Event
Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

Сравнение c конкурентами

Изменение цены

Krystal Biotech Inc Прогноз

Целевая цена

By TipRanks

15.14% рост

Прогноз на 12 месяцев

Средняя 404 USD  15.14%

Максимум 474 USD

Минимум 361 USD

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Krystal Biotech Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

8 ratings

7

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

54 / 339Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.